Abstract
Introduction
Surgery is a mainstay of rectal cancer management, but radiotherapy plays an important role in neoadjuvant treatment, especially for locally advanced cases. Neoadjuvant radiotherapy and chemoradiotherapy (CRT) both reduce the risk of local recurrence, even with optimal surgical techniques (1 3). Consequently, standard clinical practice in many parts of the world is to treat locally advanced disease with long-course CRT, with delayed surgery after 6-12 weeks. The typical long-course CRT regimen consists of [45] [46] [47] [48] [49] [50] Gy to the primary tumour and the regional lymph node stations, delivered over 5-6 weeks in daily 1.8-2.0 Gy fractions, with concomitant fluorouracilbased chemotherapy. However, neoadjuvant treatment strategies are increasingly individualised; in terms of treatment modality, radiotherapy dose and schedule, details of treatment technique, and choice of chemotherapy regimens (4) . The rationale for use of CRT may also differ across patient groups: The majority of patients with locally advanced rectal cancer will be treated with CRT in order to lower the risk of local recurrence after surgery, but some patients are initially inoperable and the aim of CRT is to improve the probability of R0 resection. Additionally, an emerging subgroup of patient receive CRT with the purpose of minimizing the need for surgical interventions.
Radiotherapy for cancer has seen a technological revolution in the last decades. Modern radiotherapy techniques allow for delivery of highly conformal, inversely optimized treatment plans. Advances in imaging including the use of computed tomography (CT) images for treatment planning and on-board CT daily imaging provide for high accuracy and precision in treatment delivery. Adaptive treatment strategies using multimodality magnetic resonance imaging (MRI) for target definition, plan adaptation, and response evaluation may be the next step forward.
In rectal cancer, these developments support individualisation of treatment planning and delivery, but also facilitate individualisation of treatment strategies, especially in terms of choice of radiotherapy dose. This review summarizes recently published evidence for the use of modern radiotherapy techniques for rectal cancer, with specific focus on intensity-modulated radiotherapy (IMRT) and arc therapy techniques, as well as adaptive treatment strategies.
Intensity modulated radiotherapy (IMRT) and volumetric arc therapy (VMAT)
Radiotherapy for rectal cancer initially used simple 2D treatment planning based on radiographs of bony pelvic structures. Treatment field configurations were either opposing fields or box field techniques, resulting in large volumes of normal tissue being irradiated. The introduction of computed tomography (CT)-based treatment planning allowed for direct identification and delineation of relevant target volumes in 3D. Combining CT-based planning with the use multi-leaf collimators (MLCs) facilitated 3D conformal radiotherapy (3D-CRT) with increased treatment accuracy and considerable reduction in normal tissue irradiation. Nonetheless, many of the lymph node targets in the pelvis are concavely shaped, and 3D-CRT techniques do not easily allow for sparing of the normal tissue contained in between those targets. For this reason, inverse planned treatment techniques, such as IMRT and VMAT (and the closely related tomotherapy technique) have increasingly been used for pelvic radiotherapy. These technologies are based on the delivery of highly modulated dose fluence from multiple directions in order to limit high dose volumes outside the treatment target; they thus support the delivery of concavely shaped dose distributions. The main rationale behind these techniques is the reduction of dose to organs at risk with the expectation of lower radiation-induced early and late toxicity.
Multiple dose planning studies have examined whether the technical advances described above also result in improved treatment plans for rectal cancer patients. Overall, these studies have demonstrated that IMRT and VMAT treatment plans do indeed deliver significantly reduced dose to bowel, bladder, and bony structures in the pelvis (see e.g. (5 7)), even taking into account common uncertainties in treatment delivery, such as day-to-day variation in organ at risk positioning (8) .
The theoretical rationale for the use of such highly conformal techniques is sound, and dose distribution improvements can clearly be achieved in clinical practice. However, the question remains as to whether this translates into clinical benefit for patients. The published evidence regarding this is more scarce (9) . A number of prospective phase I and II studies have been conducted (10 26) using IMRT/VMAT for neoadjuvant treatment of rectal cancer, but many of them are based on very few patients. No randomized trials have been completed.
Late toxicity after IMRT / VMAT
Generally speaking, limiting treatment-induced toxicity may benefit patients in (at least) two ways:
Lowering acute toxicity may allow for improved radiotherapy and chemotherapy compliance.
L long term quality of life. For rectal cancer, tolerability of standard, fluorouracil-based CRT is not a major problem, and thus introducing IMRT/VMAT in this context would conventionally aim at improving long term toxicity rates.
Unfortunately, less than a handful of studies to date have presented data on late radiationinduced morbidity after highly conformal neoadjuvant radiotherapy. A recently published prospective Belgium study (21, 27) patients evaluated for late toxicity, only one reported grade 3 non-haematological toxicity, likely related to the oxaliplatin rather than the radiotherapy. Grade 2 late non-hematologic toxicity was somewhat higher at 31%. Finally, a newly published German retrospective study compared patients treated with VMAT DCRT G concomitant 5-fluorouracil (28) . Significantly less high-grade acute and late toxicity was seen in the patient cohort treated with VMAT for late high grade toxicity, the incidences were 9% vs.
19% for VMAT and 3D-CRT, respectively.
Based on the data available, high grade late radiation-induced toxicity may not be completely avoidable, but could still be reduced compared to outcome after 3D-CRT. This makes sense from a dosimetric perspective, given the considerable overlap between the lymph node target volumes and normal pelvic tissues: some volumes of normal tissue will always be irradiated to full prescription dose, irrespectively of the conformity of the radiotherapy treatment technique.
However, data are very scarce and likely biased by improvement in surgical techniques over time.
Additionally, the studies mentioned all considered physician-scored toxicity, which will very often show discrepancy with patient-experienced toxicity (29) . There is a clear need for high quality studies measuring patient-reported outcomes using validated questionnaires.
Treatment intensification driven by IMRT / VMAT
Many of the prospective studies conducted have focused on the combination of IMRT/VMAT with experimental chemotherapy regimens. The rationale is that use of highly conformal techniques respectively. This appears to be a promising approach for select patients, and might provide a rationale for the introduction of proton therapy in rectal cancer treatment (35, 36) .
Another common approach using IMRT/VMAT in rectal cancer is to give a simultaneous integrated boost (SIB) to the primary tumour. A SIB is delivered by increasing slightly the daily treatment dose to the tumour compared to the elective volume. This allows for tumour dose escalation without extending the overall treatment time, and provides a treatment plan relatively robust to day-today variations in the positioning of the primary tumour volume. SIB techniques are challenging although not impossible (37) with 3D-CRT, and have hence gained in popularity after the introduction of IMRT and VMAT (see e.g. (15, 27) ). The combination of SIB with adaptive treatment strategies is a particularly exciting venue for research: The definition of the boost volume could e.g. be guided by response to induction chemotherapy, as investigated by Seierstad and colleagues (14) , or by response part-way through the radiotherapy treatment course (20) . The group at the San Raffaele Scientific Institute in Milan has done particularly interesting work, including investigation of the use of optimized treatment margins for safe delivery of an adaptive SIB during the second half of the treatment course (20, 38, 39) .
Technological advances and organ-preservation strategies
Organ-preserving or non-surgical treatment strategies for localized rectal cancer have been subject to considerable attention in the last decade (40, 41) . Many patients with low rectal cancers will be treated with abdominoperineal resection, resulting in a permanent stoma. Additionally, some elderly and those with major co-morbidity may not be candidates for radical surgery at all (42, 43) . Most patients treated with neoadjuvant CRT will exhibit some degree of tumour regression at the end of treatment, and a sub-group will have complete response to treatment.
Whether these patients need extensive surgery is the focus of intense debate and significant research efforts. This last year has seen considerable progress in the field with the publication of several prospective studies (44, 45) as well as a large retrospective series (46) (60, 61) . MRI is especially interesting as a modality for daily imaging for rectal cancer radiotherapy, as the primary tumour is challenging to visualize using on-board CT. MRI-guidance would allow for much more accurate daily delivery of dose-escalated treatments, but could potentially also be used for daily treatment adaptation.
To limit treatment-induced toxicity, an understanding of the relationships between dose distribution metrics and toxicity is needed to best utilize IMRT and VMAT techniques. In short, we need to know which dose constraints to use in the plan optimization process in order to produce a clinically optimal plan. However, the knowledge of dose-response and volume effects for normal tissue toxicity after CRT and surgery for rectal cancer is extremely limited. Some publications have studied acute toxicity, especially for bowel (62) and bladder (63) , but dose plan factors affecting late toxicity are not well understood, especially not for conformal treatments (64, 65) . Some discrepancies in toxicity outcomes in the previously described studies could potentially be explained by variations in the plan optimization metrics used some studies might have been conducted using treatments planned with suboptimal dose constraints.
Conclusions
IMRT and VMAT have shown promise for improving outcome for rectal cancer patients, but the published data are still limited. Dosimetric benefits have been demonstrated and many of the technical challenges have been solved, but careful quality assurance with regards to target delineation, margins and image guidance, and plan optimization constraints is needed prior to clinical implementation. Evaluation of clinical benefits in prospective clinical studies is still essential, especially in order to generate data on late toxicity using validated questionnaires. Such studies might want to focus on select groups of patients, who might be primary candidates for the use of these highly conformal, inversely planned treatment techniques. They include 1) patients with high risk of non-radical resections, i.e. very locally advanced cancers, where multi-level boost strategies might be much easier to implement using IMRT (14) ; 2) patients treated with aggressive chemotherapy regimens to limit acute toxicity; 3) patients aiming at organ preservation, e.g.
patients who might avoid surgery due to very good tumour response.
Key points
 Dosimetric benefits of IMRT/VMAT for neoadjuvant treatment of rectal cancer are wellestablished.
 Studies demonstrating clinical benefits are limited to phase I/II, and late toxicity data are scarce.
 Primary candidates for future studies of highly conformal radiotherapy include patients with high risk of non-radical resections, patients treated with aggressive concomitant -andfor clinical complete responders).
